TAZANOLAST

Details

Stereochemistry	ACHIRAL
Molecular Formula	C13H15N5O3
Molecular Weight	289.2899
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCCCOC(=O)C(=O)NC1=CC=CC(=C1)C2=NN=NN2

InChI

InChIKey=XQTARQNQIVVBRX-UHFFFAOYSA-N

InChI=1S/C13H15N5O3/c1-2-3-7-21-13(20)12(19)14-10-6-4-5-9(8-10)11-15-17-18-16-11/h4-6,8H,2-3,7H2,1H3,(H,14,19)(H,15,16,17,18)

HIDE SMILES / InChI

Molecular Formula	C13H15N5O3
Molecular Weight	289.2899
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://www.dcchemicals.com/products_Show.asp?id=4171http://meds.qlifepro.com/detail/620006023/tazanolast
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/9150859

Tazanolast, an anti-allergic and anti-asthmatic agent with selective mast-cell stabilising effects, was developed jointly by Wakamoto and Torii Pharmaceuticals.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
histamine secretion by mast cell 3 Target ID: GO:0002553 Sources: http://www.ncbi.nlm.nih.gov/pubmed/9150859	Inhibitor 8504

Conditions

Condition	Modality	Targets	Highest Phase	Product
Asthma 244 Sources: http://meds.qlifepro.com/detail/620006023/tazanolast	Palliative		Approved 8583	Unknown Approved Use Unknown
Unknown 2596

C_max

Value	Dose	Co-administered	Analyte	Population
1.18 μg/mL EXPERIMENT https://en.cnki.com.cn/Article_en/CJFDTotal-LCZZ200103013.htm	75 mg single, oral dose: 75 mg route of administration: Oral experiment type: SINGLE co-administered:		ACITAZANOLAST plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
2.18 μg × h/mL EXPERIMENT https://en.cnki.com.cn/Article_en/CJFDTotal-LCZZ200103013.htm	75 mg single, oral dose: 75 mg route of administration: Oral experiment type: SINGLE co-administered:		ACITAZANOLAST plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
2.48 h EXPERIMENT https://en.cnki.com.cn/Article_en/CJFDTotal-LCZZ200103013.htm	75 mg single, oral dose: 75 mg route of administration: Oral experiment type: SINGLE co-administered:		ACITAZANOLAST plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
4% OTHER GOV'T https://www.info.pmda.go.jp/go/interview/2/890016_1319745Q1024_2_009_1F.pdf#page=26			ACITAZANOLAST plasma	Homo sapiens

PubMed

Title	Date	PubMed
Effect of an active metabolite of the antiallergic agent tazanolast on histamine release from rat mast cells.	1997-04	9150859
[Effect of tazanolast on platelet activating factor-induced airway hyperresponsiveness in guinea pigs].	1992-09	1280089

Patents

Sample Use Guides

In Vivo Use Guide

0.01 and 0.033% aerosol inhalation.

Route of Administration: Respiratory

In Vitro Use Guide

WP-871 (Acitazanolast) may inhibit histamine release mainly by preventing the increase in intracellular Ca2+ concentration

Substance Class	Chemical Created by `admin` on `Wed Apr 02 06:54:12 GMT 2025` Edited by `admin` on `Wed Apr 02 06:54:12 GMT 2025`
Record UNII	T0248823H1
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

TAZANOL

Preferred Name

English

TAZANOLAST

Official Name

English

tazanolast [INN]

Common Name

English

Tazanolast [WHO-DD]

Common Name

English

TAZANOLAST [JAN]

Common Name

English

TAZANOLAST [MI]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C29714